Pillar_biosciences_logo
  • Investors
  • Careers
  • Investors
  • Careers
  • Company
    • Our Story
    • Leadership & Advisors
    • Pillar News
    • Distribution Partners
    • Strategic Partnership
  • Technology
  • Products
    • Portfolio Overview
    • IVD Products
    • Solid Tumor Tissue
    • Liquid Biopsy
    • Heme
    • BRCA, HRD, Methylation
    • InheritReveal™ Disease
  • Pharma
  • Resources
    • Resource Overview
    • Webinars and Presentations
    • Publications
    • Posters
  • Contact
  • Company
    • Our Story
    • Leadership & Advisors
    • Pillar News
    • Distribution Partners
    • Strategic Partnership
  • Technology
  • Products
    • Portfolio Overview
    • IVD Products
    • Solid Tumor Tissue
    • Liquid Biopsy
    • Heme
    • BRCA, HRD, Methylation
    • InheritReveal™ Disease
  • Pharma
  • Resources
    • Resource Overview
    • Webinars and Presentations
    • Publications
    • Posters
  • Contact
  • Company
    • Our Story
    • Leadership & Advisors
    • Pillar News
    • Distribution Partners
    • Strategic Partnership
  • Technology
  • Products
    • Portfolio Overview
    • IVD Products
    • Solid Tumor Tissue
    • Liquid Biopsy
    • Heme
    • BRCA, HRD, Methylation
    • Inherited Disease
  • Pharma
  • Resources
    • Resource Overview
    • Webinars and Presentations
    • Publications
    • Posters
  • Contact
  • Careers
  • Investors
  • Company
    • Our Story
    • Leadership & Advisors
    • Pillar News
    • Distribution Partners
    • Strategic Partnership
  • Technology
  • Products
    • Portfolio Overview
    • IVD Products
    • Solid Tumor Tissue
    • Liquid Biopsy
    • Heme
    • BRCA, HRD, Methylation
    • Inherited Disease
  • Pharma
  • Resources
    • Resource Overview
    • Webinars and Presentations
    • Publications
    • Posters
  • Contact
  • Careers
  • Investors

Day: December 17, 2024

Cancer Centers Look to New NGS-Based ‘Frankenpanel’ to Get Fast Info on Clinically Actionable Genes

Originally posted on Genomeweb Premium by Andrew P. Han September 12, 2024 NEW YORK – Memorial Sloan Kettering Cancer Center (MSK) is in the process of implementing a new rapid sequencing-based cancer panel to complement ongoing comprehensive genomic profiling (CGP).  The assay, branded as MSK-React, is based on a new panel from Pillar Biosciences, recently launched as […]

Pillar_biosciences_logo
Map-marker-alt Linkedin-in
Privacy Policy
© 2025 Pillar Biosciences. All rights reserved.